Background: Primary care physicians frequently encounter people with type 2 diabetes mellitus (T2DM) with discordant values for fasting glucose and HbA1c. The aim of this study was to identify the prevalence and characteristics of people in whom blood glucose and HbA1c did not match. Methods: Overall, 64 553 people with T2DM from 939 general or internal medicine practices (Disease Analyzer database, Germany; January 2013-December 2015) were analyzed. Multivariable logistic regression models were used to identify associations between baseline clinical characteristics, comorbidity, and glucose-lowering treatment and discordance of fasting glucose and HbA1c values measured at the same visit. Results: Overall, 8582 (13%) patients had fasting glucose ≥140 mg/dL and HbA1c <7% (<53 mmol/mol), and 6508 (10%) had HbA1c ≥7% (≥53 mmol/ mol) and fasting glucose <140 mg/dL. Using patients with both fasting glucose <140 mg/dL and HbA1c <7% as the reference (n = 31 834; 49%), solitary high fasting glucose values (and HbA1c <7%) were positively associated with higher age, male sex, longer diabetes duration, obesity, liver disease, low estimated glomerular filtration rate (eGFR), and glucose-lowering treatment. High HbA1c (and fasting glucose <140 mg/dL) was positively related to longer diabetes duration, obesity, neuropathy, retinopathy, low eGFR, and insulin treatment. There were lower odds of having solitary increased HbA1c ≥7% (fasting glucose <140 mg/dL) with higher age, hypertension, depression, and the number of diabetes patients (>200) per practice. Conclusions: A considerable number of people with T2DM in primary care practices have discordant fasting blood glucose and HbA1c values. People who have discordant glycemic values have different characteristics.
Introduction
Recent guidelines for the management of hyperglycemia in people with type 2 diabetes mellitus (T2DM) state that glycemic targets should be individualized using a patient-centered approach, for example by taking into account age, duration of diabetes, and comorbidity. 1 Target goals are mostly defined for HbA1c, but to achieve and maintain individualized glycemic goals, fasting or postprandial glucose values are also frequently used. 2 The A1c-Derived Average Glucose (ADAG) study established relationships between HbA1c and average glucose concentrations in type 1 diabetes mellitus and T2DM patients. 2 As an example, ADAG showed that HbA1c values between 6.5% and 6.99% (47-53 mmol/ mol) correspond to a mean fasting glucose level of 139 mg/dL in people with T2DM. 2 Although intraindividual variations in mean glucose values and HbA1c are most likely small, there is increasing evidence for a substantial between-subject variation in HbA1c values at similar glucose values ("glycation gap"). 3, 4 Discordant information with regard to HbA1c and glucose value measurements can lead to uncertainty for both patients and healthcare providers. 5 In some cases there are explanations for discordant results. A decreased turnover of red blood cells, as in iron deficiency, renal failure, or vitamin B 12 deficiency, can lead to higher HbA1c values independent of glucose values, whereas shorter life spans of red blood cells, as in hemolytic anemia or chronic liver disease, are associated with lower HbA1c concentrations. 6 In addition, HbA1c levels depend on individual characteristics, including hemoglobinopathies, age, and ethnicity. [6] [7] [8] However, even in the absence of conditions that interfere with HbA1c concentrations, there generally remains a wide variation between HbA1c and mean blood glucose values. 9 In clinical practice, discordant values for HbA1c and glucose can lead to uncertainty as to how to proceed with treatment. 5 Currently, it is unclear which proportion of people with T2DM have discordant measurements of glycemia in general practices, where most patients are mainly treated. Furthermore, the effects of patient characteristics on the relationship between HbA1c and glucose in primary care is unknown. Therefore, the aims of the present study were to estimate the prevalence of discordant fasting glucose and HbA1c values in people with T2DM and to identify clinical characteristics, comorbidities, and types of glucoselowering treatment potentially related to discordant HbA1c and glucose values.
Methods

Study design and database
Patients for the present retrospective observational study were selected from the Disease Analyzer database (IQVIA, Frankfurt, Germany). 10, 11 The Disease Analyzer database contains anonymized longitudinal data on drug prescriptions, diagnoses, and basic medical and demographic patient data obtained directly from the computer system of a representative sample of 939 general practitioners and internal medicine practices throughout Germany. 10 The database period analyzed in the present study was 1 January 2013 to 31 December 2015. First, all adult people with manifest T2DM (International Statistical Classification of Diseases and Related Health Problems 10th Revision [ICD-10] diagnosis) were selected ( Fig. 1) . Patients with at least one recorded HbA1c and fasting glucose value at the same date were included in the study. The last visit within the study period with a combined measurement of both glycemic markers was analyzed (index date). The practice People with documented BMI in the 6 months prior to index date (n=64 553) Figure 1 Selection of study sample. BMI, body mass index; FBG, fasting blood glucose; GPs, general practitioners; T2DM, type 2 diabetes mellitus.
visit records were used to determine baseline demographic characteristics 12 months before the index date. Finally, only people with one or more recorded body mass index (BMI) value within 6 months prior to the index date were included in the study.
Ethics statement
German law allows the use of anonymous electronic medical records for research purposes under certain conditions. According to this legislation, it is not necessary to obtain informed consent from patients or approval from a medical ethics committee for this type of observational study that contains no directly identifiable data. Because patients were only queried as aggregates and no protected health information was available for queries, no institutional review board approval was required for the use of this database or the completion of this study.
Data analysis
Baseline data include patient age, sex, health insurance, diabetes duration, diabetologist care, BMI, HbA1c, fasting glucose, and macrovascular (myocardial infarction, coronary heart disease, stroke) and microvascular (retinopathy, nephropathy, neuropathy) complications. Furthermore, medication with glucose-lowering drugs and the prevalence of hyperlipidemia and hypertension were assessed. Finally, glomerular filtration rate (GFR) was estimated using the Modification of Diet in Renal Disease formula:
where eGFR is estimated GFR and SCr is serum creatinine. Ethnicity was not included because of a lack of data and the low prevalence of Africans in the database sample. The cut-off for fasting glucose (140 mg/dL) corresponding to an HbA1c cut-off of 7% was based on the ADAG study. 2 Four distinct groups were defined based on HbA1c and fasting glucose values: Group 1, HbA1c <7% (<53 mmol/mol) and fasting glucose ≥140 mg/dL; Group 2, HbA1c ≥7% (≥53 mmol/mol) and fasting glucose <140 mg/dL; Group 3, HbA1c ≥7% (≥53 mmol/ mol) and fasting glucose ≥140 mg/dL; and Group 4, HbA1c <7% (<53 mmol/mol) and fasting glucose <140 mg/dL. Thus, there were two discordant (Groups 1 and 2) and two concordant (Groups 3 and 4) groups.
Descriptive statistics were calculated and group differences were assessed using Chi-squared or KruskalWallis tests. Logistic regression models were used to evaluate the relationships of Group 1 or Group 2 with age, sex, BMI, diabetes duration, diabetologist care, comorbidity, and glucose-lowering therapy using patients with well-controlled values for both (Group 4) as the reference. Two-sided tests were used and P < 0.05 was considered significant. All analyses were performed following the German good practice recommendations of secondary data analysis 12 using SAS 9.4 (SAS Institute, Cary, NC, USA).
Results
After applying the patient selection criteria, 64 533 people with T2DM were included in the study (Fig. 1) . The mean HbA1c of the whole sample was 6.9% (51.9 mmol/mol) and mean fasting glucose was 141.3 mg/dL. A solitary increased fasting glucose value (Group 1) was observed in 8582 (13.3%) T2DM patients. Solitary high HbA1c values (Group 2) were found in 6508 (10.1%) T2DM patients. Concordant results for an inadequate glycemic control (Group 3) were found in 17 629 (27.3%) patients. Finally, the largest group (Group 4) represented patients with wellcontrolled HbA1c and fasting glucose at the same visit (n = 31 834; 49.3%).
The clinical characteristics of patients with discordant (Groups 1 and 2) and concordant (Groups 3 and 4) glycemic values are given in Table 1 . Overall, mean age, having private health insurance, BMI, having had acute infections (within 2 weeks prior to the index date), and the distribution of the number of diabetes patients per practice were comparable for all four groups. Due to the large sample size, even small differences were statistically significant. Men were more frequently found in all groups with inadequate control (Groups 1 and 3). Diabetologist care was more often observed in those with high HbA1c (Groups 2 and 3). Diabetes duration was lowest in patients in whom both glycemic markers indicated good control (Group 4).
The prevalence of coronary heart disease and its major risk factors (hypertension and hyperlipidemia) was comparable in all four groups. The frequency of myocardial infarction, stroke, peripheral vascular disease, and microvascular complications (neuropathy, retinopathy, renal complications) was lowest in patients with concordant well-controlled values (Group 4). The prevalence of kidney disease defined by reduced eGFR (<60 mL/min per 1.73 m 2 ) was highest among patients with increased HbA1c values (Group 2) and was lowest among those with concordant good glycemic markers (Group 4). Depression was slightly more often The results of the logistic regression models are given in Table 2 . First, the association of clinical characteristics in people with solitary increased fasting glucose (Group 1), using people with well-controlled HbA1c and fasting glucose (Group 4) as the reference, were analyzed. The odds of having high fasting glucose despite good HbA1c values increased significantly with higher age, male sex, longer diabetes duration, higher BMI, and liver disease ( Table 2) . Hyperlipidemia was related to lower odds of having solitary increased fasting glucose. Finally, any medical treatment of T2DM, in particular, insulin therapy was associated with increased odds of having high fasting glucose (Group 1).
Furthermore, the relationships between clinical characteristics with solitary increased HbA1c values and good fasting glucose (Group 2 vs Group 4) were analyzed. Significantly increased odds of having high HbA1c values were found for diabetes duration >5 years, increased BMI, retinopathy, and acute infections. Very low eGFR values (<30 mL/min 1.73 m 2 ) were also related to increased odds of having discordant results both for HbA1c and fasting glucose measurements. Borderline significance was found for neuropathy (P = 0.06). Furthermore, glucose-lowering therapy, in particular insulin therapy, was related to high HbA1c values. Conversely, significantly lower odds were observed for higher age, hypertension, and depression. A higher number of diabetes patients per practice was related to lower odds of having high HbA1c values (and low fasting glucose).
Discussion
The novel finding of the present descriptive study is that almost 25% of people with T2DM in primary care practices have discordant glycemic values. Higher age, higher BMI, male sex, liver disease (fatty liver), and longer diabetes duration were related to increased odds of having solitary high fasting glucose. A solitary increased HbA1c value was found in 10% of T2DM patients. Longer diabetes duration (>5 years), obesity, retinopathy, and acute infections were independently related to increased odds of having high HbA1c. Both solitary high fasting glucose and HbA1c values were related to increased prescription use of glucose-lowering medication, in particular insulin therapy, and to increased BMI and longer diabetes duration.
The effects of clinical characteristics on the relationship between glucose values and HbA1c in T2DM in primary care have not been investigated. Longitudinal data from 16 clinical trials have been analyzed to study the association between mean blood glucose (MBG; 24-h profiles) and HbA1c in 8927 T2DM patients. 13 The association of clinical characteristics with the change in HbA1c at a given MBG was modeled and age >65 years was related to a small but significant decrease in HbA1c at a given MBG (−0.14%). 13 A combined analysis of two studies that also included people without diabetes (Screening for Impaired Glucose Tolerance [SIGT] study, National Health and Nutrition Examination Survey [NHANES]) found increased HbA1c levels at a given blood glucose level for elderly individuals.
14 In the present study, which was based on people with T2DM only, we found lower odds of having solitary increased HbA1c values with increased age, which is in line with the clinical studies. 13 In addition, higher age was related to a higher chance of having solitary increased fasting glucose. Thus, differences in study samples (diabetes patients vs general population) may explain the previous conflicting results.
In line with the present study, there was no effect of sex on HbA1c values at a given MBG in a previous clinical study in T2DM. 13 However, we found higher odds of having solitary fasting glucose in men than in women. A higher prevalence of impaired fasting glucose has been observed in men than in women. 15, 16 The underlying causes for this sex difference are not well understood, but differences in body fat distribution and hormones between men and women may contribute to this dimorphism. As expected, obesity and longer diabetes duration were both related to increased odds of having either solitary increased fasting glucose or HbA1c values. Based on the recent meta-analysis of clinical trials, BMI did not seem to affect the relationship between HbA1c and glucose. 13 This apparent discrepancy with the results of the present study may be explained by higher glucose values in the present study.
The higher HbA1c and fasting glucose values with longer diabetes duration most likely reflect the progressive loss of β-cell function over time. 17 It is of note that diabetologist care was not related to either increased fasting glucose or HbA1c, although T2DM patients with higher HbA1c values were more often in specialized diabetes care.
With regard to comorbidity and complications, the odds of having solitary increased HbA1c was higher in patients with retinopathy and a trend was also found for neuropathy. There was no association of increased fasting glucose values and good HbA1c with the odds of having microvascular complications. In previous studies, HbA1c has been consistently related to the risk of retinopathy, as summarized by Kowall and Rathmann. 6 Kidney disease assessed by low eGFR was strongly related to discordant HbA1c and fasting glucose values. It is well established that in chronic kidney disease HbA1c may yield biased results for glycemic control. 18 As an example, a low correlation was recently found between HbA1c and fasting glucose (r = 0.52) in people with diabetes and severe chronic kidney disease. 18 It is of note that no relationships were observed between discordant glucose and HbA1c values (Groups 1 and 2) and the chance of having macrovascular complications, underlining that other cardiovascular risk factors (hypertension, hyperlipidemia) are more important. 19, 20 Lower odds of having solitary increased HbA1c values (Group 2) were found with hypertension, which may be due to the fact that the primary care physicians are treating patients with hypertension more intensively because of the known poor prognosis. Similar intensive treatment may explain the finding that hyperlipidemia was related to lower odds of having solitary increased fasting glucose values, which needs to be confirmed.
Liver diseases, which mostly include fatty liver, were related to an increased chance of having solitary fasting glucose (Group 1), but there was no relationship with increased HbA1c (Group 2). This difference may reflect either underlying pathomechanisms (i.e. fasting hyperglycemia due to increased endogenous glucose production) or falsely lower HbA1c determination in patients with elevated liver enzymes. 21 Depression was related to lower odds of having solitary high HbA1c (Group 2). Although depression has been linked to suboptimal diabetes treatment, it has also been shown that a reduction of depressive symptoms improves glycemic control. 22, 23 Finally, unexpectedly, acute infections were related to higher HbA1c (Group 2) but not to fasting glucose values (Group 1). The few studies on communityacquired infections and glycemic control did not find a strong link either with HbA1c or fasting glucose. 24 Finally, compared with no medical treatment, any glucose-lowering therapy was related to increased odds of having either high fasting glucose or HbA1c (Groups 1 and 2). In particular, insulin treatment was related to substantially increased odds of having solitary high HbA1c. These findings reflect the attempt to achieve good glycemic control by intensifying glucose-lowering treatment. 1 Interestingly, a higher number of diabetes patients per practice was related to lower odds of having increased HbA1c values. A similar trend was found for fasting glucose. The most likely explanation for this is that a high number of diabetes patients indicates better training and expertise in diabetology of the primary care physicians.
The findings of the present study are clinically relevant. Physicians who only rely on HbA1c measurements in T2DM overlook a substantial proportion of people with inadequate fasting glucose values: HbA1c values do not reflect intraindividual and intraday glycemic excursions. 25 Therefore, fasting glucose adds valuable information for both patients and healthcare providers. More optimal glycemic control can be achieved by monitoring both HbA1c and fasting glucose and choosing the appropriate treatment option. Finally, it would be interesting to compare the longterm risk of complications related to monitoring either HbA1c or fasting glucose.
When interpreting the results of the present study, several limitations should be taken into account. First, HbA1c and fasting glucose measurements were not standardized. In addition, assessment of comorbidity relied on the recording of ICD-10 codes by primary care physicians only. Data on socioeconomic status (e.g. education, income) and lifestyle-related risk factors (e.g. smoking, alcohol, physical activity) were also lacking. Finally, because this study was primarily explorative, we have not adjusted our analyses for multiple testing.
In conclusion, the present real-world study shows that fasting glucose and HbA1c values are not concordant in approximately 25% of T2DM patients in primary care. The odds of having discordant glucose and HbA1c values are related to patient characteristics (including age, sex, diabetes duration, BMI), glucoselowering drug treatment, comorbidity (liver disease, hypertension, depression), and complications (neuropathy, retinopathy, low eGFR).
